PBS questions value of pumps for type 1
There is not enough evidence to conclusively support the superior efficacy or safety of insulin pump therapy for type 1 diabetes over multiple daily injections in any age group, according to a PBS post-market review.
The systematic review of randomised controlled trials shows the overall strength of evidence is “low to very low”, with minimal benefit from insulin pump therapy on HbA1c and no effect on hypoglycaemia.
The observed benefit of insulin pump therapy compared with multiple daily injections showed a reduction in HbA1c levels, ranging from 0.1–0.22% in children and adolescents, and 0.19–0.30% for adults.
The difference did not reach the 0.5% reduction generally accepted to be of clinical significance, according to the review, which is open for comment until July 21.